Benevolentai interim results for the six months ended 30 june 2024

London--(business wire)--regulatory news: benevolentai ("benevolentai" or “the company" or “the group”) (euronext amsterdam: bai), a leader in applying advanced ai to accelerate biopharma drug discovery, announces its unaudited interim results for the six months ended 30 june 2024. peter allen, chair, said: “i was delighted to join the board as chair in may, along with the other new non-executive directors, to support the leadership of the company. benevolentai has consistently been a pioneer a.
CEO Ratings Summary
CEO Quant Ranking